FXTAS is rare among Portuguese patients with movement disorders: *FMR1* premutations may be associated with a wider spectrum of phenotypes

Ana I Seixas1, José Vale2, Paula Jorge3, Isabel Marques3, Rosário Santos3, Isabel Alonso1, Ana M Fortuna3, Jorge Pinto-Basto1,6, Paula Coutinho4, Russell L Margolis5, Jorge Sequeiros1,6 and Isabel Silveira1*

**Abstract**

The fragile X-associated tremor/ataxia syndrome (FXTAS) is a late-onset neurodegenerative disorder caused by expansions of 55-200 CGG repeats in the 5′UTR of the *FMR1* gene. These *FMR1* premutation expansions have relatively high frequency in the general population. To estimate the frequency of *FMR1* premutations among Portuguese males with non-familial, late-onset movement disorders of unknown etiology, we assessed CGG repeat size in males with disease onset after the age of 50 and negative or unknown family history for late-onset movement disorders, who were sent for SCA, HD, or PD genetic testing at a reference laboratory. The selected patients had a primary clinical diagnosis based on one of the following cardinal features of FXTAS: ataxia, tremor, or cognitive decline. A total of 86 subjects were genotyped for the CGG repeat in the *FMR1* gene. We detected one patient with an expansion in the premutation range. The frequency of *FMR1* premutations was 1.9% (1/54) in our group of patients with ataxia as the primary clinical feature, and 1.2% (1/86) in the larger movement disorders group. In the family of the FXTAS case, premutation-transmitting females presented a history of psychiatric symptoms, suggesting that, given the wide phenotypical expression of the premutation in females, neuropsychiatric surveillance is necessary. In conclusion, genetic testing for FXTAS should be made available to patients with adult-onset movement disorders to enable adequate genetic counseling to family members.

**Findings**

Expansions of a CGG repeat tract in the 5′UTR region of the *FMR1* gene causes the fragile X syndrome (FXS), the most common inherited cause of mental retardation. FXS is an X-linked disorder, characterized by moderate to severe mental impairment, facial dysmorphism and behavioral abnormalities in males, and by milder symptoms in some carrier females [1]. Full mutations (more than 200 CGGs) cause FXS, as they lead to loss of function due to gene silencing mediated by abnormal methylation patterns [2,3]. Normal alleles range in length from 5 to 44 triplets, and repeats of 45-54 CGGs are “grey zone alleles” of unknown biological significance [4]. Premutations range from 55 to 200 CGGs and have been associated with two different phenotypes: females are at a higher risk for premature ovarian insufficiency (POI) [5]; whereas males may be affected by the fragile X-associated tremor/ataxia syndrome (FXTAS) [6,7].

FXTAS is characterized by progressive cerebellar ataxia, tremor, and parkinsonism with bradykinesia and rigidity; other symptoms may include cognitive decline and peripheral neuropathy [8]. Neuroradiological findings show generalized brain atrophy with white matter lesions in the middle cerebellar peduncle [9,10]. Clinical criteria for FXTAS were proposed by Hagerman et al. [11]: presence of a *FMR1* premutation, one major clinical sign (gait ataxia or intention tremor), and one major finding on neuroimaging (white matter lesions in middle cerebellar peduncles). Histopathology of FXTAS post-mortem brains revealed loss of Purkinje cells in the cerebellum, and presence of eosinophilic intranuclear inclusions in neurons and astrocytes of the cortex [12]. The pathogenic mechanism of FXTAS seems to be different from that of FXS: abnormal methylation does not
occur with premutation and, therefore, a loss of function mechanism is unlikely. Instead, it appears to be associated with toxic RNA species containing long CGG tracts [13].

Penetrance of FXTAS in males carrying FMR1 premutations increases from 17% in the sixth decade to 75% after the age of 80. FXTAS in females has been reported [14,15], but appears to be rare. Though only 1/4000 men have the full mutation, frequency of premutations is much greater: 1/1000 in Caucasian males [16]. The high frequency of FMR1 premutations in the general population was taken as an indication that they could represent a major cause of non-familial cases of late-onset ataxia. A review of the literature reported that the frequency of FMR1 premutations, in all combined ataxia cases, was 1.3% in men and 0.24% in women [17]. As ataxia in FXTAS is often associated with tremor and/or cognitive decline, it is plausible that some cases of FXTAS could present for testing with a clinical diagnosis other than cerebellar ataxia; therefore, other movement disorders have also been screened for FMR1 premutations. The combination of all studies published up to 2008, in patients with movement disorders other than ataxia (including essential tremor, parkinsonism, and multiple system atrophy), gives a total frequency of CGG repeat length in the FXTAS range of 0.37%, higher than the overall population rate [17].

Here, we present the first study on the frequency of FMR1 premutations in a sample of Portuguese males sent for genetic testing, with late-onset movement disorders characterized by one or more of the FXTAS cardinal clinical features (ataxia, tremor, or cognitive decline). Additionally, we investigated transmission of the FMR1 repeat among FXTAS family relatives.

Cases were ascertained from a pool of patients referred to a reference laboratory in Portugal for genetic testing for neurological diseases. Inclusion criteria were as follows: males with onset after age 50 years, absent or unknown family history of autosomal dominant late-onset movement disorders, clinical diagnosis of late-onset movement disorder (spinocerebellar ataxia, SCA; Huntington disease, HD; or Parkinson disease, PD), and absence of SCA, HD, or relevant PD mutations. Only those presenting with ataxia, parkinsonism, and/or cognitive decline were included. Genomic DNA was isolated from peripheral blood using standard techniques. All patients gave their informed consent. Assessment of (CGG)n, in FMR1 was performed by PCR, improved for amplification of GC-rich sequence regions, as described previously [18]. PCR products were visualized on agarose gel stained with ethidium bromide and compared to a control with 30 CGGs; PCR products that appeared larger were further analyzed by automated fragment analysis in a 3730xl DNA Analyzer (Applied Biosystems, Foster City, CA) for assessment of repeat number. Premutation status was established for alleles with 55-200 CGGs. Full mutations were detected by double digestion with EcoRI and Eagl of 10 μg of genomic DNA, followed by electrophoresis in agarose gels and blotting onto Hybond N+ membranes (Amersham, UK). Probe Ox1.9 was labeled by P32-dCTP nick translation and hybridized according to standard methodology. Autoradiography was carried out for 24-48 hours at -70°C, using intensifying screens and Kodak X-Omat-RP films.

A total of 86 male patients were identified as candidates, following application of the defined criteria. Demographics and clinical features are summarized in Table 1; 54/86 patients (63%) had ataxia, and 50/86 (58%) had no known family history of late-onset movement disorders. We identified one patient with approximately 95 CGGs. Frequency of premutations in the total sample was 1.2%. In the subset of patients with ataxia, frequency was 1.9%.

The patient carrying the FMR1 premutated allele was a 73-year-old male, who reported onset at age 51, and was sent for genetic testing of SCAs (Figure 1). He had an initial clinical diagnosis of essential tremor that did not improve upon treatment with beta-blockers and antiepileptic drugs. Further examination at age 66 revealed a mild cerebellar syndrome with gait ataxia and dysarthria, difficulties with memory and executive function, and neurosensorial deafness. MRI showed diffuse atrophy of the cerebellum and cerebellar peduncles. At age 72, the patient presented with aggravated cognitive

| Cardinal clinical feature | Ataxia (n = 54) | Tremor (n = 4) | Cognitive deficits (n = 28) | Total (N = 86) |
|---------------------------|----------------|---------------|---------------------------|---------------|
| Age (mean ± SD)           | 67.7 ± 9.1     | 59.0 ± 8.6    | 70.0 ± 9.2                | 680 ± 9.3     |
| Age-of-onset (mean ± SD)  | 59.0 ± 6.8     | 54.0 ± 1.4    | 60.5 ± 6.7                | 59.2 ± 6.7    |
| With additional cardinal features (n) | 13  | 1  | 4  | 18 |
| Family history (n)        |                |               |                           |               |
| None                      | 33             | 3             | 14                        | 50            |
| Unknown                   | 21             | 1             | 14                        | 36            |

Table 1 Demographics and clinical features of the patient population
deficits. These clinical features and radiological findings confirmed a probable FXTAS diagnosis.

After identification of this FXTAS patient, we studied the family and discovered a clinical history of FXS (Figure 1) in two first cousins of the proband (IV:5 and IV:6). Information provided by the proband’s son and by sisters of the FXS patients also suggests a history of psychiatric disease among premutation-transmitting females; III:2 had an admission to a psychiatric hospital. In addition, IV:3 was reported to have a tremor and cognitive deficits, but no neurological exam or DNA were available. Consanguinity was present in the family, thus increasing the risk for genetic diseases. No additional information was obtained for this family. Two patients carrying ‘grey zone’ alleles of 49 and 52 repeats (a frequency of 2.3% in the total sample) were also found. In the general population, the frequency of grey zone alleles is 3-4/100 males [16,19].

This study presents the first FXTAS screening in the Portuguese population of males with adult-onset movement disorders sent for genetic testing. The frequency of FMR1 premutations was 1.9% (1/54) in patients with ataxia as the cardinal clinical feature, which is within the range reported by multiple studies (0% to 4.1%), and 1.2% (1/86) in our global sample. A review of all such studies (Table 2) shows that the FMR1 premutation rate among men with cerebellar syndromes averages 1.2%. Ascertainment of subjects, criteria used and the population studied may explain some of the frequency variability. As ascertainment via test request for SCA could fail to detect other FXTAS cases, we also included individuals referred for testing for PD and HD. We also applied stringent criteria, as only males with onset above age 50 years and no suggestive family history of late-onset movement disorders were included. However, we found no FMR1 premutations in 32 patients with a movement disorder other than ataxia, which is consistent with the literature (Table 2). Only 3 premutation carriers (a rate of 0.3%) have been found in movement disorder cohorts that exclude ataxia cases - two had an initial diagnosis of multisystem atrophy (important in the differential diagnosis of ataxia), while the other was referred for HD testing.

Our study provides further evidence that a primary diagnosis of cerebellar ataxia is still the cardinal feature of the vast majority of FXTAS cases. There has been
debate as to whether genetic testing for FXTAS should be included in screening panels for late-onset movement disorders. We conclude that, though the prevalence of FXTAS appears low, genetic testing should be made available to patients with late-onset movement disorders, particularly with a clinical diagnosis of ataxia, and in agreement with the guidelines suggested by Berry-Kravis et al. [9].

FXTAS appears to be quite rare among women carrying premutations, but a recent study describes a higher rate of neuropsychiatric symptoms among daughters of FXTAS patients, including memory and balance problems, tremor, and psychiatric disturbances [20]. Motor and mental dysfunction was recently reported in a FXTAS premutation carrier in a mother-daughter transmission [21]. Another study identified a high lifetime risk of mood and anxiety disorders among male and female carriers of the \( FMR1 \) premutation [22]. These findings concur with our observation that, in the family of the Portuguese FXTAS patient, there is an increased risk for motor and/or mental dysfunction in relatives carrying the premutation.

### Table 2 Frequency of \( FMR1 \) premutations among male patients with adult-onset movement disorders

| Sample origin       | Ascertainment via                              | Inclusion criteria | Premutation rate | Study                                |
|---------------------|------------------------------------------------|--------------------|------------------|--------------------------------------|
| United Kingdom      | Referral for genetic test of SCA                | Ataxia             | 2/59             | (Macpherson et al., 2003) [23]       |
| USA                 | Clinical diagnosis of ET                       | ET                 | 0/40             | (Garcia Arocena et al., 2004) [24]   |
| USA                 | Clinical diagnosis of MSA                      | MSA                | 0/40             | (Garland et al., 2004) [25]          |
| USA                 | Referral for genetic test of SCA               | Ataxia, age > 50   | 1/167            | (Milunsky and Maher 2004) [26]       |
| Singapore           | Clinical diagnosis of movement disorder        | ET, age > 45       | 0/34             | (Tan et al., 2004) [27]              |
| Japan               | Clinical diagnosis of MSA                      | MSA                | 0/36             | (Yabe et al., 2004) [28]             |
| Germany             | Referral for genetic test of SCA               | Ataxia, AOO > 50   | 0/269            | (Zuhlke et al., 2004) [29]           |
| Europe (mixed)      | Clinical diagnosis of MSA or related            | MSA                | 0/76             | (Biancalana et al., 2005) [30]       |
| Italy               | Clinical diagnosis of SCA                      | Ataxia             | 6/275            | (Brussino et al., 2005) [31]         |
| Europe (mixed)      | Clinical diagnosis of MSA                      | MSA*               | 2/253            | (Kamm et al., 2005) [32]             |
| USA                 | Referral for genetic test of SCA and HD        | Cerebellar disease | 1/73             | (Seixas et al., 2005) [18]           |
| Mixed               | Clinical diagnosis of PD                       | Basal ganglia disease | 0/6           | (Toft et al., 2005) [33]             |
| Belgium             | Referral for genetic test of SCA               | Ataxia, age > 50   | 0/414            | (Van Esch et al., 2005) [34]         |
| Spain               | Clinical diagnosis of SCA                      | Ataxia, isolated; age > 45 | 5/122 | (Rodriguez-Revengega et al., 2007) [35] |
| USA                 | Referral for genetic test of SCA               | Ataxia, age > 50   | 1/87             | (Rodriguez-Revengega et al., 2007) [35] |
| Poland              | Clinical diagnosis of SCA                      | Ataxia, age > 50   | 1/286            | (Adams et al., 2008) [17]            |
| Brazil              | Clinical diagnosis of movement disorder        | Ataxia, and/or tremor, and/or parkinsonism, age > 45 | 1/178 | (Rajkiewicz et al., 2008) [36]       |
| Spain               | Referral for genetic test of HD                | HD                 | 0/66             | (Reis et al., 2008) [37]             |
| United Kingdom      | Clinical diagnosis of SCA, HD, and PD          | Ataxia             | 0/105            | (Wardle et al., 2009) [39]           |
| Portugal            | Clinical diagnosis of SCA, Referral for genetic test of SCA, HD, and PD | Ataxia, isolated; AOO > 50 | 1/54 | This study |
|                     | Tremor or cognitive decline                   |                    | 0/32             |                                      |

Total of ataxia referrals: 20/1724
Total of movement disorder referrals (other than ataxia): 3/1119

SCA, spinocerebellar ataxia; ET, essential tremor; MSA, multisystem atrophy; PD, Parkinson disease; APD, atypical Parkinson disease; AOO, age of onset. *Includes proven, possible, and probable MSA.
In light of this, and given the complex phenotypic expression of the \textit{FMR1} expansions, psychological and neurologic surveillance (in addition to screening for POI in females) may be necessary for relatives of FXS and FXTAS patients, and perhaps for carriers in general. The complex inheritance and wide spectrum of phenotypes associated with the \textit{FMR1} (CGG)$_n$ reinforces the importance of genetic counseling in these families.

Acknowledgements

We would like to thank the patients and their families for participating in the study, and E. Cruz, A.M. Lopes, V. Mendes, and J. Cerqueira for technical assistance. This work was supported by research grant PIC/IC/82897/2007, FCT (Fundação para a Ciência e Tecnologia) and co-funded by FEDER. A.L.S. was the recipient of a scholarship from FCT (SFRH/BD/30702/2006). The experiments performed complied with the currently accepted ethical norms and national laws.

Author details

1. UniGene, IBMC - Instituto de Biologia Molecular e Celular, Universidade do Porto, Porto, Portugal. 2. Department of Neurology, Hospital de Egas Moniz, Lisboa, Portugal. 3. Centro de Genética Médica Dr. Jacinto Magalhães, INSA, Porto, Portugal. 4. Department of Neurology, Hospital de São Sebastião, Feira, Portugal. 5. Division of Neurobiology, Department of Psychiatry, Johns Hopkins University School of Medicine, Baltimore, USA. 6. ICBAS, Universidade do Porto, Portugal.

Authors’ contributions

Study concept and design: AIS and IS. Acquisition of data: AIS, JV, IM, RS, IA, AMF, JPB and PC. Critical revision of the manuscript for important intellectual content: AIS, RLJM and IS. Study supervision: IS. All authors read and approved the final manuscript.

Competing interests

The author declares that they have no competing interests.

Received: 3 March 2011 Accepted: 3 June 2011 Published: 3 June 2011

References

1. Ashley CT Jr, Warren ST: Trinucleotide repeat expansion and human disease. Annu Rev Genet 1995, 29:703-728.
2. Verkerk AJ, Pieretti M, Sutcliffe JS, Fu YH, Kuhl DP, Pozzutti A, Reiner D, Richards S, Victoria MF, Zhang FP, Eussen BE, van Ommeren GB, Blonden LAJ, Riggins GJ, Chastain JL, Kunst CB, Galjaard H, Caskey CT, Nelson DL, Oostra BA, Warren ST: Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell 1991, 65:905-914.
3. Pieretti M, Zhang FP, Fu YH, Warren ST, Oostra BA, Caskey CT, Nelson DL: Absence of expression of the FMR-1 gene in fragile X syndrome. Cell 1991, 65:817-822.
4. Maddalena A, Richards CS, McGinnis MJ, Brothman A, Desnick RJ, Gire RE, Hirsch B, Jacky P, McDowell GA, Popovich B, Watson M, Wolff DJ: Technical standards and guidelines for fragile X: a first of a series of disease-specific supplement to the Standards and Guidelines for Clinical Genetics Laboratories of the American College of Medical Genetics. Quality Assurance Subcommittee of the Laboratory Practice Committee. Genet Med 2001, 3:200-205.
5. Sullivan AK, Marcus M, Epstein MP, Allen EG, Anido AE, Paquin JF, Yadav-Shah M, Sherman SL: Association of FMR1 repeat size with ovarian dysfunction. Hum Reprod 2005, 20:402-412.
6. Hagerman RJ, Leehey M, Heinrichs W, Tassone F, Wilson R, Hills J, Grigsby J, Gage B, Hagerman PJ: Intention tremor, parkinsonism, and generalized brain atrophy in male carriers of fragile X. Neurology 2001, 57:127-130.
7. Garcia Arcazen D, Breeze KE, Hagerman PJ: Distribution of CGG repeat sizes within the fragile X mental retardation 1 (FMR1) homologue in a non-human primate population. Hum Genet 2003, 113:371-376.
8. Hagerman RJ, Hall DA, Coffey S, Leehey M, Bourgeois J, Gould J, Zhang L, Servan A, Berry-Kravis E, Olichney J, Miller JW, Fong AL, Carpenter R, Bodine C, Gane LW, Rainn E, Hagerman H, Hagerman PJ: Treatment of fragile X-associated tremor ataxia syndrome (FXTAS) and related neurological problems. Clin Interv Aging 2008, 3:251-262.
9. Berry-Kravis E, Abrams L, Coffey SM, Hall DA, Greco C, Gane LW, Grigsby J, Bourgeois NJ, Finucane B, Jacquemont S, Brunberg JA, Zhang L, Lin J, Tassone F, Hagerman PJ, Hagerman RJ, Leehey MA. Fragile X-associated tremor/ataxia syndrome: clinical features, genetics, and testing guidelines. Mov Disord 2007, 22:2018-2030.
10. Jacquemont S, Hagerman RJ, Leehey M, Grigsby J, Zhang L, Brunberg JA, Greco C, Des Portes V, Jardini T, Levine R, Berry-Kravis E, Brown WT, Schaeffer S, Kissel J, Tassone F, Hagerman PJ: Fragile X premutation tremor/ataxia syndrome: clinical, molecular, and neuroimaging correlates. Am J Hum Genet 2003, 72:869-878.
11. Hagerman PJ, Hagerman RJ: The fragile-X premutation: a maturing perspective. Am J Hum Genet 2004, 74:805-816.
12. Greco CM, Hagerman RJ, Tassone F, Chudley AE, Del Bigio MR, Jacquemont S, Leehey M, Hagerman PJ: Neuronal intranuclear inclusions in a new cerebellar tremor/ataxia syndrome among fragile X carriers. Brain 2002, 125:1760-1771.
13. Tassone F, Iwahashi C, Hagerman PJ: FMR1 RNA within the intranuclear inclusions of fragile X-associated tremor/ataxia syndrome (FXTAS). RNA Biol 2004, 1:119-125.
14. Hagerman RJ, Leavitt BR, Farzin F, Jacquemont S, Greco CM, Brunberg JA, Tassone F, Hess D, Harris SW, Zhang L, Jardini T, Gane LW, Ferranti J, Ruiz L, Leehey MA, Grigsby J, Hagerman PJ: Fragile-X-associated tremor/ataxia syndrome (FXTAS) in females with the FMR1 premutation. Am J Hum Genet 2004, 74:1051-1056.
15. Jacquemont S, Hagerman RJ, Leehey MA, Hall DA, Levine RA, Brunberg JA, Zhang L, Jardini T, Gane LW, Harris SW, Herman K, Grigsby J, Greco CM, Berry-Kravis E, Tassone F, Hagerman PJ: Penetration of the fragile-X associated tremor/ataxia syndrome in a premutation carrier population. JAMA 2004, 291:460-469.
16. Crawford DC, Meadow KL, Newman JL, Taft LF, Pettay DL, Gold LB, Hersey SJ, Hinkle EF, Stanfield ML, Holmgreen P, Yeang-Allospich M, Boyle C, Sherman SL: Prevalence and phenotype consequence of FRAXA and FRAXE alleles in a large, ethnically diverse, special education-needs population, Am J Hum Genet 1999, 64:495-507.
17. Adams SA, Steenbok KJ, Thibodeau SN, Lindor NM: Premutations in the \textit{FMR1} gene are uncommon in men undergoing genetic testing for spinocerebellar ataxia. J Neurol Genet 2008, 2:27-32.
18. Seixas AL, Maurer MH, Lin M, Callahan C, Ahuja A, Matsuura T, Ross CA, Hisama FM, Silveira I, Margolis RL: FXTAS, SCA10, and SCA17 in American patients with movement disorders. Am J Med Genet A 2005, 136:87-89.
19. Pasillas PC, Smani C, Hettenger JA, Holden JJ, Lawson JS, Chalfoux M, Wing M, Walker M, Leggo J: Frequencies of "grey-zone" and premutation-size \textit{FMR1} CGG-repeat alleles in patients with developmental disability in Cyrus and Canada. Am J Med Genet 1999, 84:195-197.
20. Chonchuya W, Nguyen DV, Au J, Campos L, Berry-Kravis EM, Lohse K, Mu Y, Utari A, Hervey C, Wang L, Sorenson P, Cook K, Gane L, Tassone F, Hagerman RJ: Clinical involvement in daughters of men with fragile-X-associated tremor ataxia syndrome. J Neurol 2010, 278:46-50.
21. Rodriguez-Reverena L, Pagonabarraga I, Gomez-Anson B, Lopez-Mourelo Q, Madrigal I, Xuncuà M, Kulisievsky J, Mila M: Motor and mental dysfunction in mother-daughter transmitted FXTAS. Neurology 2010, 75:1370-1376.
22. Bourgeois JA, Servant AL, Casillas EM, Hess D, Schneider A, Yang Y, Kaur I, Cogswell JB, Nguyen DV, Hagerman RJ: Lifetime prevalence of mood and anxiety disorders in fragile premutation carriers. J Clin Psychiatry 2011, 72:175-82.
23. Macpherson J, Waghorn A, Hamsmans S, Jacobs P: Observation of an excess of fragile-X premutations in a population of males referred with spinocerebellar ataxia. Hum Genet 2003, 112:619-620.
24. Garcia Arcazen D, Luiss ED, Tassone F, Gilliam TC, Ottman R, Jacquemont S, Hagerman PJ: Screen for expanded \textit{FMR1} alleles in patients with essential tremor. Mov Disord 2004, 19:930-933.
25. Garland EM, Vnencak-Jones CL, Biaggioni I, Davis TL, Montine TJ, Robertson D: Fragile X gene premutation in multiple system atrophy. J Neurol Sci 2004, 227:115-118.
26. Milunsky JM, Maher TA: Fragile X carrier screening and spinocerebellar ataxia in older males. Am J Med Genet 2004, 125A:320.

27. Tan BK, Zhao Y, Puong HY, Law HY, Chan LL, Yew K, Tan C, Shen H, Chandran VR, Teh LC, Yih Y, Pawar R, Yong MC, Ng IS: Fragile X premutation alleles in SCA, ET, and parkinsonism in an Asian cohort. Neurology 2004, 63:362-363.

28. Yabe I, Soma H, Takei A, Fujik N, Sasaki H: No association between FMR1 premutations and multiple system atrophy. J Neurol 2004, 251:1411-1412.

29. Zuhlke C, Budnik A, Gehlken U, Dalski A, Purmann S, Naumann M, Schmidt M, Burk K, Schweiger E: FMR1 premutation as a rare cause of late onset ataxia—evidence for FXSAs in female carriers. J Neurol 2004, 251:1418-1419.

30. Biancalana V, Toft M, Le Ber J, Tison F, Scherrer E, Thibodeau S, Mandel JL, Brice A, Farrer MJ, Durr A: FMR1 premutations associated with fragile X-associated tremor/ataxia syndrome in multiple system atrophy. Arch Neurol 2005, 62:962-966.

31. Brussino A, Gellera C, Saluto A, Mariotti C, Arduino C, Castellotti B, Camerlingo M, de Angelis V, Oru L, Tosca P, Migone N, Taroni F, Brusco A: FMR1 gene premutation is a frequent genetic cause of late-onset sporadic cerebellar ataxia. Neurology 2005, 64:145-147.

32. Kamm C, Healy DG, Quinn NP, Wullner U, Moller JC, Geser F, Burk K, Borglum AD, Pellecchia MT, Tolosa E, del Sorbo F, Nilsson C, Bandmann O, Sharma M, Mayer P, Gasteiger M, Haworth A, Ozawa T, Lees AJ, Short J, Giunti P, Holinski-Feder E, Big T, Wichmann HE, Wenning GK, Wood NW, Gasser T, European Multiple System Atrophy Study Group: The fragile X tremor ataxia syndrome in the differential diagnosis of multiple system atrophy: data from the EMSA Study Group. Brain 2005, 128:1855-1860.

33. Toft M, Aasly J, Bisciglio G, Adler CH, Uitti RJ, Krygowska-Wajs A, Lynch T, Wizolek ZK, Farrer MJ: Parkinsonism, FXTAS, and FMR1 premutations. Mov Disord 2005, 20:230-233.

34. Van Esch H, Dom R, Bex D, Salden I, Caekebeke J, Wilbail A, Boeghgraef M, Legius E, Fryns JP, Matthijs G: Screening for FMR1 premutations in 122 older Flemish males presenting with ataxia. Eur J Hum Genet 2005, 13:121-123.

35. Rodriguez-Revenga L, Gomez-Anson B, Munoz E, Jimenez D, Santos M, Tintore M, Martin G, Brieva L, Mila M: FXTAS in Spanish patients with ataxia: support for female FMR1 premutation screening. Mov Disord 2007, 35:324-328.

36. Rajkiewicz M, Sulek-Piatkowska A, Krysa W, Zdzienicka E, Szirkowiec W, Zaremba J: Screening for premutation in the FMR1 gene in male patients suspected of spinocerebellar ataxia. Neurol Neurochir Pol 2008, 42:497-504.

37. Reis AH, Ferreira AC, Gomes KB, Aguilar MJ, Fonseca CG, Cardoso FE, Pardini VC, Carvalho MR: Frequency of FMR1 premutation in individuals with ataxia and/or tremor and/or parkinsonism. Genet Mol Res 2008, 7:74-84.

38. Rodriguez-Revenga L, Santos MM, Sanchez A, Pujol M, Gomez-Anson B, Badenas C, Jimenez D, Madrigal I, Mila M: Screening for FXTAS in 95 Spanish patients negative for Huntington disease. Genet Test 2008, 12:135-138.

39. Wardle M, Majounie E, Muzaimi MB, Williams NM, Morris HR, Robertson NP: The genetic aetiology of late-onset chronic progressive cerebellar ataxia. A population-based study. J Neurol 2009, 256:543-548.